Xenon Pharmaceuticals (XENE) Depreciation & Amortization (CF) (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $587000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 10.93% year-over-year to $587000.0 in Q1 2026; TTM through Mar 2026 was $2.5 million, a 6.15% decrease from a year earlier, with the FY2025 full-year figure at $2.5 million, down 0.66% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $587000.0, down from $611000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for XENE reached as high as $1.7 million in Q3 2023 and fell as low as -$629000.0 in Q4 2023.
• Historically, Depreciation & Amortization (CF) has averaged $538588.2 across 5 years, with a median of $602000.0 in 2023.
• On a YoY basis, Depreciation & Amortization (CF) climbed as much as 384.36% in 2023 and fell as far as 312.5% in 2023.
• Year by year, Depreciation & Amortization (CF) stood at $296000.0 in 2022, then slumped by 312.5% to -$629000.0 in 2023, then jumped by 205.88% to $666000.0 in 2024, then dropped by 8.26% to $611000.0 in 2025, then slipped by 3.93% to $587000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $587000.0 in Q1 2026, $611000.0 in Q4 2025, and $641000.0 in Q3 2025.